Summit Therapeutics
11 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer (NCT07228832) | Summit Therapeutics | 2025-11-18 |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 (NCT06767514) | Summit Therapeutics | 2025-02-27 |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients (NCT05899608) | Summit Therapeutics | 2023-10-26 |
| Phase III Study of AK112 for NSCLC Patients (NCT06396065) | Summit Therapeutics | 2023-05-04 |
| Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects (NCT04802837) | Summit Therapeutics | 2021-05-19 |
| Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection (NCT03595553) | Summit Therapeutics | 2019-01-28 |
Track Summit Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.